Molecular biology tools: proteomics techniques in biomarker discovery.

Friedrich Lottspeich, Josef Kellermann, Eva-Maria Keidel
{"title":"Molecular biology tools: proteomics techniques in biomarker discovery.","authors":"Friedrich Lottspeich, Josef Kellermann, Eva-Maria Keidel","doi":"10.3109/00365513.2010.493359","DOIUrl":null,"url":null,"abstract":"<p><p>Despite worldwide efforts biomarker discovery by plasma proteomics was not successful so far. Several reasons for this failure are obvious. Mainly, proteome diversity is remarkable between different individuals and is caused by genetic, environmental and life style parameters. To recognize disease related proteins that could serve as potential biomarkers is only feasible by investigating a non realizable large number of patients. Furthermore, plasma proteomics comprises enormous technical hurdles for quantitative analysis. High reproducibility of blood sampling in clinical routine is hard to achieve. Quantitative proteome analysis has to struggle with the complexity of millions of protein species comprising typical plasma proteins, cellular leakage proteins and antibodies and concentration differences of more than 1011 between high and low abundant proteins. Therefore, no successful quantitative and comprehensive plasma proteome analysis is reported so far. A novel proteomics strategy is proposed for biomarker discovery in plasma. Instead of comparing the plasma proteome of different individuals it is recommended to analyze the proteomes of different time points of a single individual during the development of a disease. This strategy is realized by the use of plasma of the Bavarian Red Cross Blood Bank, were three million samples are stored under standardized conditions. To achieve reliable data the isotope coded protein labelling proteomics technology was used.</p>","PeriodicalId":76518,"journal":{"name":"Scandinavian journal of clinical and laboratory investigation. Supplementum","volume":"242 ","pages":"19-22"},"PeriodicalIF":0.0000,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/00365513.2010.493359","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Scandinavian journal of clinical and laboratory investigation. Supplementum","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3109/00365513.2010.493359","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 7

Abstract

Despite worldwide efforts biomarker discovery by plasma proteomics was not successful so far. Several reasons for this failure are obvious. Mainly, proteome diversity is remarkable between different individuals and is caused by genetic, environmental and life style parameters. To recognize disease related proteins that could serve as potential biomarkers is only feasible by investigating a non realizable large number of patients. Furthermore, plasma proteomics comprises enormous technical hurdles for quantitative analysis. High reproducibility of blood sampling in clinical routine is hard to achieve. Quantitative proteome analysis has to struggle with the complexity of millions of protein species comprising typical plasma proteins, cellular leakage proteins and antibodies and concentration differences of more than 1011 between high and low abundant proteins. Therefore, no successful quantitative and comprehensive plasma proteome analysis is reported so far. A novel proteomics strategy is proposed for biomarker discovery in plasma. Instead of comparing the plasma proteome of different individuals it is recommended to analyze the proteomes of different time points of a single individual during the development of a disease. This strategy is realized by the use of plasma of the Bavarian Red Cross Blood Bank, were three million samples are stored under standardized conditions. To achieve reliable data the isotope coded protein labelling proteomics technology was used.

分子生物学工具:生物标记物发现中的蛋白质组学技术。
尽管全世界都在努力通过血浆蛋白质组学发现生物标志物,但至今仍未取得成功。失败的原因显而易见。主要是由于遗传、环境和生活方式等因素的影响,不同个体的蛋白质组具有显著的多样性。要识别可作为潜在生物标志物的疾病相关蛋白,只有对大量无法实现的患者进行调查才可行。此外,血浆蛋白质组学在定量分析方面存在巨大的技术障碍。临床常规血液采样的高重现性很难实现。定量蛋白质组分析必须与数百万种蛋白质的复杂性作斗争,这些蛋白质包括典型的血浆蛋白质、细胞泄漏蛋白质和抗体,高含量和低含量蛋白质之间的浓度差异超过 1011。因此,迄今为止还没有成功进行定量和全面血浆蛋白质组分析的报道。为发现血浆中的生物标记物,我们提出了一种新的蛋白质组学策略。与其比较不同个体的血浆蛋白质组,不如分析单个个体在疾病发展过程中不同时间点的蛋白质组。巴伐利亚红十字会血库在标准化条件下储存了 300 万份血浆样本。为了获得可靠的数据,使用了同位素编码蛋白质标记蛋白质组学技术。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信